Published in Women's Health Weekly, November 27th, 2003
For the quarter, the company reported sales of $35.1 million and net income of $4.7 million, or $0.11 per fully diluted share, on a GAAP (generally accepted accounting principles) basis.
This compares to sales of $20.7 million and a net loss of $11.6 million, or $0.32 per diluted share, reported in the same period of 2002. The company's net loss for the third quarter of 2002 included a $12.3 million purchased in-process research and development write-off related to a patent right acquisition from Bonutti Research.
"We are pleased with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly